



Extracellular Vesicle-Based Delivery System for Cancer and Neurodegenerative Disease Treatment

Guest Editors:

Dr. Eva Costanzi

Dipartimento Di Medicina E
Chirurgia, Università degli Studi
di Milano-Bicocca, Piazza
dell'Ateneo Nuovo, 1-20126
Milan, Italy

Dr. Stefano Persano

Department of Oncology and
Hematology-Oncology,
Università degli Studi di Milano,
20122 Milano, Italy

Prof. Dr. Stefano Loporatti

CNR NANOTEC—Istituto di
Nanotecnologia, Via Monteroni,
73100 Lecce, Italy

Deadline for manuscript
submissions:

31 January 2025

Message from the Guest Editors

Extracellular vesicles (EVs) have emerged as promising nanocarriers capable of crossing biological barriers and delivering therapeutic agents with high specificity and reduced toxicity. The most clinically approved delivery vehicles are represented by liposomes, which are EV-like structures sharing structural similarities with EVs, but differing in composition and ease of production. EVs offer greater biological complexity and potential for drug loading, but face manufacturing and quality control challenges. Future applications involve the use of EV-based platforms for the delivery of immunotherapeutics, such as mRNA-based drugs. Overall, the field of EVs could be critical for advancing targeted therapies, which can significantly contribute to improving the outcomes of patients with cancer or neurodegenerative conditions.

This Special Issue aims to gather innovative research and comprehensive reviews on the development and application of EV-based delivery systems. We seek to explore the mechanisms, challenges, and clinical potential of these systems (by EVs and EV-like structures), aligning with cutting-edge therapeutic strategies and drug/gene delivery technologies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma